Journal
APPETITE
Volume 156, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.appet.2020.104807
Keywords
Obesity; Diabetes; Hormones; Bariatric surgery
Categories
Funding
- Diabetes UK
Ask authors/readers for more resources
The increase in obesity has led to a rise in bariatric procedures, with RYGB being considered the most efficacious in achieving sustained weight loss and metabolic improvements, particularly in patients with type 2 diabetes and cardiovascular diseases. Multiple alterations in gut hormone secretion after RYGB have been shown to play a role in reducing food intake and improving glucose homeostasis.
The alarming rise in obesity and relative lack of pharmacotherapies to treat, what is becoming a global epidemic, has necessitated that an increasing number of bariatric procedures be performed. Several surgical techniques have been developed during the last 50 years and the advent of laparoscopic surgery has increased the safety and efficacy of these procedures. Bariatric surgery is by a substantial margin, the most efficacious means of achieving sustained weight loss maintenance in patients with obesity. Roux-en-Y gastric bypass surgery (RYGB) elicits the most favourable metabolic outcomes with attendant benefits for type 2 diabetes and, cardiovascular disease as well as endocrine disorders and cancers in females. RYGB is the most extensively studied bariatric procedure regarding mechanism of action. In this review we catalogue the multiple alterations in secretion of gut hormones (ghrelin, obestatin, cholecystokinin, GLP-1, PYY, GIP, oxyntomodulin, glicentin and GLP-2) occurring after RYGB and summarise evidence indicating that these changes play a role in the reduction of food intake and im-provements in glucose homeostasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available